Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotechnology Startup Investors in Ireland in February 2025

Last updated: Feb 2025 A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups based in Ireland. We rank investors based on the number of investments they made in Biotechnology companies from Ireland. We update this investor list every month.

Top 50 Biotechnology Startup Investors in Ireland in February 2025

Investor	Biotechnology Ireland investments
Enterprise Ireland	30
SOSV	19
Western Development Commission	12
Irrus Investments	7
Kernel Capital	7
Fountain Healthcare Partners	6
AIB Seed Capital Fund	6
Atlantic Bridge	5
Seroba Life Sciences	5
European Investment Bank	4
HBAN Medtech Syndicate	4
HBAN	4
Act Venture Capital	3
Furthr VC	3
Atlantic Bridge University Fund	3
The Yield Lab Europe	3
Boole Investment Syndicate	3
ARCH Venture Partners	2
Elkstone Capital Partners	2
Infinity Capital	2
Enterprise Equity	2
SVG Ventures	2
Lightstone Ventures	2
Ascentifi	2
SVG Ventures	2
HealthCap	2
EarlyBirdCapital	1
Eoghan Quigley	1
Carragh Holdings	1
Silicon Valley Bank	1
Johnson & Johnson Innovation – JJDC	1
Earlybird Venture Capital	1
Cedas Foundation	1
Novartis Venture Fund	1
Apicap	1
HBM-MedFocus	1
MML Capital Partners	1
Inventages Venture Capital Investment Inc.	1
KBI Biopharma	1
The Yield Lab	1
Third Swedish National Pension Fund	1
Woodford Investment Management	1
EarlyBird	1
Blue Wire Capital	1
Alimentos Ventures	1
Claret Capital Partners	1
Clay Capital	1
John Purdy	1
Medtech Syndicate Nominee	1
Carbery Group	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
NUA Surgical — NUA Surgical is an award-winning Irish MedTech company developing innovative solutions in obstetrics and gynaecology.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Funding Round, Series A
Ireland, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Peroptyx — Peroptyx is a platform that provides managed solutions for machine learning. At Peroptyx, they have assembled and pre-screened a qualified network of data evaluators across the globe. They strategically match ideal evaluators with each product to ensure authentic experiences through consistency and appropriate real-world contexts.
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.

Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.

Investment focus

Medical Device, Biotechnology, Health Care
Seed, Funding Round, Series A
Ireland, Sweden, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generaterevenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
Ireland, United Kingdom, France

Portfolio highlights

Cirdan — Cirdan provides highly reliable, innovative LIS & imaging solutions for the acceleration & enhancement of diagnosis, optimized for pathology & clinical lab.
Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
Pilot Photonics — Welcome to Pilot Photonics, a laser product development company in Dublin, Ireland. We provide optical frequency combs and tunable lasers.

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
Ireland, United States, France

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Mainstay Medical — Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.
XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up andexploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto.Atlantic Bridge brings together a unique team of technology entrepreneurs, experienced managers, finance professionals, and investment experts. The team contains a wealth of international business experience across Europe, the UK and the US. They have worked together in various capacities for the last 30 years, bringing a true partnership approach to their firm and their investments. Its investors include the founders, leading institutional investors, and private investors with a track record of investment in successful technology companies.Atlantic Bridge has developed a unique and differentiated strategy that focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale-up of technology companies in Europe and the US. This approach is highly differentiated and has delivered strong performance results to date.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Funding Round
United States, Ireland, United Kingdom

Portfolio highlights

Mindgard — Mindgard is an AI security company that helps enterprise to test, detect, and respond to cyber threats against their AI models.Given that businesses are increasingly focused on offering AI-driven services such as LLMs, securing this new way of conducting business is equally important. Mindgard ensures that your business can safely and securelymove into the new AI world and continue to protect your digital assets, brand and reputation.Our platform enables enterprise customers to determine, detect, and remediate against any adversarial attack vulnerabilities within all their AI models. This answers the “What is my AI risk?” and “How do I mitigate my AI risk?” questions that currently cannot be answered using traditional Cyber Security platforms. By designing our platform from the ground up to integrate with existing AI and Cyber Security operational tooling, Mindgard can be seamlessly added to your organization, providing repeatable and automated AI model vulnerability testing.The Mindgard platform has been in development for over 4 years based on cutting edge PhD-led, AI & cyber security research, also used by the global Intelligence Community. As well as providing a library of adversarial attacks based on deep research, leveraging our platform that can automate repeated security testing, detection, and response across the entire AI estate. By leveraging the Mindgard platform, our clients free up precious AI and cyber security resources and at the same time understand, detect, and mitigate risks across their entire AI model portfolio, which currently takes too long and is too expensive. Our platform ensures that business can rapidly embrace LLMs and other AI technologies whilst protecting their digital assets, brand, and reputation within the new AI world.
Mindgard Ltd — Mindgard Ltd specializes in providing comprehensive AI security solutions to enterprises. Our operations center around a sophisticated platform designed to determine, detect, and remediate adversarial attack vulnerabilities within AI models. The platform is built on over four years of PhD-led research in AI and cyber security, ensuring advancedprotection that traditional Cyber Security platforms cannot offer.Our platform integrates seamlessly with existing AI and Cyber Security tools, enabling automated and repeatable vulnerability testing across the entire AI estate. This integration allows enterprises to efficiently assess and mitigate risks, optimizing their AI and cyber security resources.Key operational features include: - Automated Security Testing: Utilizing a library of adversarial attacks, our platform conducts thorough and repeated security tests to identify vulnerabilities. - Detection and Response: The platform continuously monitors AI models for threats and provides rapid detection and response capabilities to neutralize potential attacks. - Seamless Integration: Designed for compatibility with existing operational tools, our platform can be easily incorporated into current security infrastructures.Mindgard Ltd's operations ensure that businesses can securely adopt and innovate with AI technologies while protecting their digital assets, brand, and reputation in the evolving AI landscape.
Insight Terra — Insight Terra supports data driven risk management in critical situations where business operations, people and the environment all come together.

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Ireland, United States, United Kingdom

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
ShiraTronics — ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany.
Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

Investment focus

Biotechnology, Health Care, Energy
Debt Financing, Post-IPO Debt, Funding Round
Germany, France, The Netherlands

Portfolio highlights

Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
Greenlight Biosciences — Next Generation Crop Protection
Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.

HBAN Medtech Syndicate

Investment focus

Medical Device, Medical, Health Care
Seed, Funding Round, Series B
Ireland

Portfolio highlights

FeelTect — FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous.
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

HBAN is dedicated to raising the profile of business angel investment as an asset class on the island of Ireland and to promote the creation of business angel syndicates.

Investment focus

Health Care, Medical Device, Software
Seed, Funding Round, Series A
Ireland, United Kingdom, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Educatly — We help you get into the University of your dreams. We are the only platform with all the information you need to Study Abroad
Quantmatix — Improve the quality, efficiency and timing of your investment decisions. Quantmatix is a systematic tool for professional investors to evaluate instruments, dynamically shape portfolios and drive performance.

Technology-focused, investing capital and expertise to fuel growth in the most promising ideas and companies. Raised c.€600m across multiple funds and invest from seed to growth.We look for companies with potentially cutting-edge, category-defining businesses in markets including application software, IT infrastructure, communications, Internetand mobile. We help founders create and scale businesses globally. We work as a small team with diverse strengths accessing a community of over 200 founders. The teams and companies we back scale their investor base as they scale their business execution and ambition. We work closely with them in this process. Over the past 25 years have built a broad network of US and European investors and founders that share our vision and approach.Act is based in Dublin, Ireland.Our most recent funds are supported by the European Investment Fund.

Investment focus

Software, Information Technology, SaaS
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Trustap — Learn how we make buying & selling online safe & secure, every time. Create an account for free today!
Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
Mavarick AI — Explore Mavarick AI's Carbon Accounting Software Platform. Get accurate carbon emissions accounting data and generate auditable reports with ease.

Furthr VC invests in transformative tech. Furthr Venture Capital invests in scalable, early-stage companies. We help Ireland's next generation of technology.

Investment focus

Medical, Medical Device, Health Care
Seed, Funding Round, Pre-Seed
Ireland

Portfolio highlights

Trustap — Learn how we make buying & selling online safe & secure, every time. Create an account for free today!
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.

We invest in entrepreneurs with the ambition to create world-class companies of scale.

Investment focus

Medical Device, Health Care, Big Data
Seed, Series A, Funding Round
Ireland, United States

Portfolio highlights

CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
ProVerum Medical — ProVerum Medical is an early stage medical device startup for the treatment of Benign Prostatic Hyperplasia (BPH).
Tympany Medical — Tympany Medical is a Needs-driven, Innovative MedTech StartUp based in the West of Ireland

The Yield Lab Europe is a €50m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.

Investment focus

AgTech, Agriculture, Biotechnology
Seed, Series A, Funding Round
Ireland, France, United Kingdom

Portfolio highlights

Oligofeed — We developed a supplement boosting bee immunity. Our non-toxic bee-feeding product reduces bee mortality and improves the production of the hives.
Marama Labs — Marama Labs provides an integrated chemical analysis platform that empowers customers to optimize their production processes and match their products and brands to customer needs, with ease.
Micron AgriTech — Micron Agritech, driving the future of sustainable animal health. Run a FEC worm or fluke test with your phone and get results in minutes.

Boole Investment Syndicate invests in new technology start-up's with scalability.

Investment focus

Medical Device, SaaS, EdTech
Seed, Funding Round
Ireland, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
FeelTect — FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

Elkstone is an investment firm, focusing on entrepreneurs, senior executives, institutional LPs, the venture community, and the Irish diaspora.The objective of the organization is to boost the economic value and overall well-being of the island of Ireland by expanding a network, facilitating deserving investments, and delivering excellentinvestment performance.

Investment focus

Software, Health Care, Medical
Seed, Series A, Funding Round
Ireland, United Kingdom, United States

Portfolio highlights

Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.
Jentic Technology — Jentic Technology builds integration layer for AI, enabling developers to connect agents to the World.

Infinity Capital are hypothesis-driven investors - constantly calibrating ideas through a Silicon Valley/technology network that they've been building for over two decades. Their extensive technology and operating backgrounds, combined with over a dozen years each of successful startup investing, have been essential in buildingcredibility and a reputation that resonates with entrepreneurs.

Investment focus

Semiconductor, E-Commerce, Electronics
Series B, Funding Round, Series D
United States, Ireland, Canada

Portfolio highlights

AltraTech — Next Generation Molecular Detection Discover Altratech Next Generation Molecular Detection Discover Altratech At Altratech, our mission is to enable next generation molecular detection.
BioSapien — BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline ofindications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
Core Starters — Core Starters services startups and investors through blockchain-based decentralized services to solve real problems.

Enterprise Equity (or EEVC) is an excellent for providing capital to early stage and expanding business throughout Ireland.

Investment focus

Software, Information Technology, Medical Device
Funding Round, Seed, Series B
Ireland, United States, United Kingdom

Portfolio highlights

Phorest — Join 8000+ spas, barbers, hair, beauty and nail salon owners using the #1 management, scheduling, POS and appointment booking system. Try Phorest now!
SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

We are a Venture & Innovation Platform Advancing the Food & Agriculture Industries We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the food and agriculture industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

scoutlabs — We're building the world's densest digital trap network to accurately gauge insect pest pressure. This helps millions of farmers in precisely combating crop-eating insects, accelerating a transition to more sustainable methods. Good for the farmer, the environment and for our food security
Verdi Expeditions — Verdi is building the world's first truly scalable platform for farm automation. We work with the world's largest food brands to grow better and more sustainable crops.
Heritable Agriculture — Making plants programmable

Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing inbreakthrough life science companies during a time of unique opportunity in space.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Ireland, Singapore

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Cala Health — Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology

Discover start-up investing made simple. Access VC-led rounds, build your portfolio, and unlock growth at Ascentifi

Investment focus

Medical, Health Care, Medical Device
Funding Round, Series A
Ireland

Portfolio highlights

CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
X-BOLT Orthapaedics — X-Bolt Trauma Solutions for osteoporotic bone fixation. FDA 510(k) approved. Clinical studies include the WHITE One (n=100) and WHITE Four (n=1,140) randomized control trials.

We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

FarmWise — FarmWise provides technology-based services that allow farmers to streamline farm operations and increase food production efficiency.
Napigen — We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration.
Iamus Technologies — Iamus Technologies Limited is an Artificial Intelligence & Robotics company based in Ireland that has developed poultry specific robotic technology that empowers poultry farmers to make better and safer production decisions. Over the last 2 years we have been working globally with poultry processors in identifying KPIs that our robots cancontinuously gather on the ground in poultry sheds and feedback instantly to both producer and the relevant personnel back at the processing plant. Results to date are impressive with automatic and accurate data recovery from the birds on every part of the floor and analysis with real-time intervention now possible. These factors are key in addressing the growing demands of modern, intensive broiler production with the Iamus robot & platform meeting these requirements.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.

EarlyBirdCapital, Inc. (“EBC”) is a registered broker-dealer1 and member of the Financial Industry Regulatory Authority, Nasdaq Stock Market, Inc., Municipal Securities Rule Making Board, and Securities Insurance Protection Corporation2. EBC is a boutique investment bank that has developed an expertise in working with smaller capitalizationcompanies, special situation investments and Special Purpose Acquisition Companies (SPACs:tm:), a new concept they pioneered and developed that involves publicly-traded, industry-specific acquisition funds.

Investment focus

Medical, Health Care, Biotechnology
Seed
Ireland

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.

Eoghan Quigley

Investment focus

Medical, Biopharma, Health Care
Seed
Ireland

Portfolio highlights

Beyondbmi — Beyondbmi is an expert led medical approach to weight loss. We provide a convenient and scientific telehealth program designed to help your reach your health goals.

Carragh Holdings

Investment focus

Biotechnology, Bioinformatics
Series A
Ireland

Portfolio highlights

Kastus Technologies — Kastus is embedded into glass during manufacturing. Creating the world's first surface that constantly cleans itself of over 99% of germs and viruses, including Covid 19. It works 24/7, for the lifetime of the glass.

Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.

Investment focus

Software, Health Care, Biotechnology
Debt Financing, Series B, Series A
United States, United Kingdom, Canada

Portfolio highlights

BILT — 3D instructions for assembly & installation. The free BILT app guides with voice, text & 3D animated images for a better customer experience.
MoneyLion — Our financial app is an easy way to borrow, save, invest, and earn. An all in one mobile banking app. Take control of your financial future today. Join now!
Solar Landscape — Solar Landscape is the leading developer of community solar projects on commercial & industrial rooftops in the United States.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Cala Health — Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
G.I. Windows — G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States.

Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. With EUR 2 billion under management,eight IPOs and 30 trade sales, Earlybird is one of the most established and active venture capital firms in Europe.

Investment focus

Software, Information Technology, Health Care
Series A, Seed, Series B
Germany, United States, United Kingdom

Portfolio highlights

eyva.ai — The decisonOS for beauty and personal care
GEMMABio — GEMMABio, a new therapeutics company, will serve as the research and innovation arm to speed the research of and global access to life-changing advanced therapies for those living with rare diseases.
Upvest — Upvest empowers financial institutions to offer investment products in their app with a modular, scalable, and accessible API. Upvest brings together everything that’s required to offer a broad range of investment products on the website and app. They are connected to the world’s leading asset providers and exchanges to provide the bestinvestments, at the best prices and execution speed.

Cedas Foundation

Investment focus

Biotechnology, Organic, Biopharma
Seed
Ireland, United States

Portfolio highlights

Hexafly — Hexafly is a biotechnology company that develops materials and sources form insects for aquafeed, chitin, and plant nutrition industry. It offers products from the sustainable farming of insects such as insect oil, protein, frass, and chitin. The company was founded in 2016 and headquartered in Kells, Meath, Ireland.
BioSapien — BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline ofindications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.

Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Apicap offers investment and co-investment solutions for managers, wealthy private clients and institutional investors.

Investment focus

Software, Information Technology, Mobile
Funding Round, Series A, Series B
France, United States, Turkey

Portfolio highlights

Crowdaa — Crowdaa is a mobile-only music store where producers decide how to distribute and monetise their content.
Feelbat — FEELBAT - Feelbat
Karma Koma — Karma Koma is specializes in retail and French and international distribution with multi-brand resellers.

HBM-MedFocus

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B
Ireland, United States

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Viseon — Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation.

MML Capital Partners is an independent investment firm, with over twenty years of history, focused on providing capital to businesses for expansion/acquisitions, management-led equity deals, recapitalisations and buy-outs.

Investment focus

Manufacturing, Packaging Services, Information Technology
Private Equity, Funding Round, Series A
United Kingdom, France, United States

Portfolio highlights

RAVL — Step into the future with RAVL and our revolutionary financial service technology solutions. We're not just building tech; we're crafting the future of financial services. Unleashing potential, one innovative solution at a time. Let's strategize, deliver, and repeat excellence together.
SCPACK GROUP — SCPACK GROUP is a packaging and containers manufacturing company for wine, cosmetics and more.
Ross-shire Engineering — Trusted water technology solutions and products for purifying drinking water, recycling effluent and cleaning water in industrial processes.

Inventages Venture Capital Investment Inc is an investment arm of Nestle SA specializing in PIPES, seed, early, mid, and late venture investments. The firm seeks to invest in middle market and mature companies. It provides mezzanine and bridge financing. The firm seeks to invest in health care, life sciences, cosmeceuticals, pharmaceuticals,enabling technologies and services, and diagnostic and medical devices. Within the pharmaceutical sector, it typically invests in small molecules, proteins, antibodies, vaccines, phytopharmaceuticals, natural compounds, botanicals, antibiotics, and therapeutics. Within the diagnostic sector, it focuses on genetic materials, biomarkers, pathological markers, genetic profiles, protein profiles, pharmacogenomics, food and environmental safety, genetically modified organism detection and trading, medical monitoring, diagnostic and analytical tools, and quality control. Within enabling technologies and services it primarily invests in novel packaging, process and production technologies, supply chain management, innovative materials and resources, delivery systems for active compounds, encapsulation and prevention, food services, extraction and fractionation of biological materials, consumer relation management, green biotechnology, smell and taste modifying technologies, genomics, proteomics, metabolomics, screen and characterization technologies, chemical and biological engineering, and innovative preventive and therapeutic concepts. It also invests in companies involved in the prevention of medical foods, nutraceuticals, cosmoceuticals, nutrition, innovative food, functional food, dietary and food supplements, oral and skin care, immune modulation and stimulation, and health and disease management.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Accera — Accera is a biotechnology company that engages in the discovery and development of therapeutic drugs for neurodegenerative diseases. It offers Ketasyn, a molecule for Alzheimer's, Parkinson's, and age-associated memory impairment. It was founded in 2001 and is headquartered in Broomfield, Colorado.
XOLUTION — XOLUTION is the most advanced reclosable beverage container solution. Already in its prototype state, the new XO resealable can won the Can of the Year Award in Dubai in 2009 (Winner Silver - Category Prototype) and was enhanced and refined since, involving extensive market research and field testing. With the can now entering the consumer beveragemarket, they are confident that the product resembles a step forward for XOLUTION in becoming the market leader in this field. XOLUTION GmbH is headquartered in Munich, Germany. In 2008, Marc von Rettberg was named Chief Executive of the company. He joined Christian Bratsch, Vice President R&D, to introduce innovative designs to the beverage packaging industry for reclosable beverage cans.Rettberg and Bratsch established new product design guidelines with a clear focus on values and benefits for the entire supply chain. The innovative beverage can ends were required to offer easy usage to the consumer (intuitive, easy to open and reseal), easy integration for the beverage filler in the existing processes (no major adjustments to the filling line), easy handling for the can maker (XO reclosable can ends based on standard shells), and improved commercialization for the beverage brand (unique branding options). And, of course, the focus was set on providing these benefits at a reasonable overall cost.In 2009, Can Maker Magazine recognized the XOLUTION innovative resealable can with the Silver Award in the Prototype category for the XO-400 reclosable beverage can lid. Since Time-to-Market is a key challenge for all innovators, Rettberg and Bratsch have created a competitive advantage of rapid prototyping and testing capabilities in their Salzburg R&D Center. XOLUTION GmbH is managed by one of the most competent teams in the business. With long-term experiences in their respective fields, their leading specialists guarantee the best coverage of all business areas from prototyping, R&D and product management to trading and distribution. With their knowledge, the XO Resealable Can was successfully converted from a simple vision to a technologically sophisticated product that will have a significant influence on the canned beverage market.
Ripple Foods — Ripple Foods offers a nutritious & delicious milk alternative that is 100% dairy-free, vegan, nut-, lactose- & gluten-free. Discover more about Ripple milk!

KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO / CMO) offering Cell Line Development, Process Analytical & Formulation Development, Clinical & Commercial Manufacturing, and more.

Investment focus

Biotechnology, Life Science, Medical
Seed, Series A, Series D
United States, Ireland

Portfolio highlights

Absci — A better, faster path to new medicines. We translate ideas into drugs with an AI-powered approach to biologic drug discovery and cell line development.
GlycoSeLect — GlycoSeLect Ltd specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs).
Comera Life Sciences — ReForm Biologics is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient toproduce. It was founded in 2014 and is based in Woburn, Massachusetts.

The Yield Lab invests in AgriFood Tech companies with technologies focused on crops, animal health, digital agriculture, logistics, and food ingredients. Initial investments range from $100,000 – $1.5M.

Investment focus

Agriculture, Biotechnology, AgTech
Seed, Series A, Convertible Note
United States, Argentina, Brazil

Portfolio highlights

Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
Sundew — Targeting water-borne pests and diseases
Kaffe Bueno — Kaffe Bueno upcycles coffee waste into active and functional ingredients for cosmetics, nutraceuticals and functional foods.

Third Swedish National Pension Fund employs different investment strategies in the interest of spreading risk and protecting pensions for current and future pensioners. The firm was founded in 2001 and is headquartered in Stockholm, Sweden.

Investment focus

Biotechnology, Battery, CleanTech
Funding Round, Post-IPO Equity
Sweden, Denmark, Ireland

Portfolio highlights

Saniona — Improving the lives of rare disease patients around the world through scientific innovation.
Northvolt — Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.

Woodford Investment Management is a privately owned investment firm manages equity mutual funds. At Woodford, they don’t want to be just another fund management company. They want to create something different and better for their investors and they feel strongly that existing and potential clients are entitled to understand what they are doingwith their money.As investors, they are active, engaged, long-term, disciplined, diligent and focused. That’s a lot of things to say about their selves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along.Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United Kingdom, United States, Ireland

Portfolio highlights

Revolut — Join 40+ million customers globally using Revolut to send money to 160+ countries, hold up-to 36 currencies in app, spend in 150+ currencies, and manage their money.
Atom Bank — Savings accounts, a range of mortgages & business loans, you'll find it all with Atom bank. App-based and designed to be hassle-free. Download the app today.
Evofem Biosciences — Lithera is developing products for aesthetic medicine to address both medical and lifestyle indications. Its lead product is an injectable treatment to achieve local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA registered drugs proven safe and effective in other indications, its product targets and stimulates natural fatmetabolism and achieves non-ablative, non-surgical fat tissue reduction in specific locations.

EarlyBird is a postal snacking service that delivers healthy snacks to its users’ doorstep. It provides its users with TasteBox, 5 healthy snacks and 2 unique teas, to help them through the working week. Its TasteBox also contains music and art from up and coming artists. EarlyBird was launched in 2014 and is based in London, England.

Investment focus

Financial Services, FinTech, Health Care
Seed, Series A, Pre-Seed
Germany, Ireland, Romania

Portfolio highlights

Sikoia — Streamline your decision-making with centralized customer data, comprehensive case management, and automated risk evaluation without complicated integrations.
Noscendo — Noscendo operates as a diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections.
Goodlegal — Goodlegal is the One-Stop-Shop for all your Legal needs. Get an out-of-the-box Legal Infrastructure Platform to handle all your problems.

Investing globally in Frontier & Consumer businesses at pre-seed or seed.

Investment focus

Software, Advanced Materials, Art
Seed, Pre-Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Faircraft — A sustainable, lab-grown alternative to animal leather.
Praktika — Automated 1-1 tutorship experience with generative AI Avatar tutors
River Platform Company — Orchestrate IRL events at massive scale by leveraging volunteer hosts from your community. Monetize community events with our sponsorship marketplace.

Accelerate innovation in aquaculture feed and technology.

Investment focus

Farming, Aquaculture, Therapeutics
Seed
Ireland

Portfolio highlights

MicroSynbiotiX — Microsynbiotix, an Irish-based Biotechnology company making microalgal oral vaccines for aquaculture

Claret Capital provides specialty debt financing to European growth businesses, predominantly in the technology, life sciences and environmental sectors. Typical loan sizes range from €1M-€40M with the flexibility to do larger transactions opportunistically.They look for investment opportunities in high growth business with proven managementteams in need of capital to fuel organic growth, acquisitions, equipment purchases, bridge loans and various forms of recapitalization.

Investment focus

Software, Information Technology, Mobile
Debt Financing, Funding Round, Series A
United Kingdom, Germany, United States

Portfolio highlights

Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
Holidu — Holidu is one of the fastest-growing travel tech companies worldwide that aims to finally make the search and booking of vacation rentals easy. Its search engine uses proprietary image recognition technology to compare the prices of millions of rental properties across hundred of websites including Airbnb, Booking.com, and Homeaway. This enablesusers to quickly find the ideal accommodation and to save up to 55% on their bookings. It was founded in 2014 by brothers Johannes and Michael Siebers and is headquartered in Munich, Bayern, Germany.
Exoticca — Exoticca develops an online platform intended to facilitate travel booking. The company's platform offers holiday packages which includes flights, accommodation, meals, guides and private transports, for exotic locations all around the world, enabling travelers to book travel packages online at competitive prices.

VisVires New Protein is a pioneering investor focused on solving the persistent challenges of our food and feed system.

Investment focus

Food and Beverage, Biotechnology, Health Care
Series A, Series B, Funding Round
France, Israel, Germany

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Infinite Roots — Mushlabs is a biotech company using fermentation to create the next generation of sustainable foods from the roots of mushrooms.
Abolis Biotechnologies — Abolis is a biotech innovator providing sustainable, tailor-made solutions for food, health, cosmetics, and chemicals industries. Embrace biotechnology for a better future.

John Purdy

Investment focus

Software, FinTech, Medical
Seed, Funding Round
Ireland

Portfolio highlights

dimply — The experience & engagement platform for financial enterprises.
Beyondbmi — Beyondbmi is an expert led medical approach to weight loss. We provide a convenient and scientific telehealth program designed to help your reach your health goals.
FlowForma — Unlock competitive advantage with FlowForma, the #1 no code digital process automation software & business process management tool. Get a free trial now!

Medtech Syndicate Nominee

Investment focus

Medical, Health Care, Medical Device
Seed, Series A, Funding Round
Ireland

Portfolio highlights

Kite Medical — Kite medical has developed a novel device for detecting Kidney Reflux in children with Urinary Tract Infections. The non-invasive diagnostic solution for kidney reflux removes the need for complicated procedures and a hospital visit. Kidney reflux is the most common urological disorder in childhood, affecting up to three per cent of young children.It is most prevalent from six months to five years of age. The condition may resolve as the child gets older, but left undiagnosed and untreated it can lead to permanent kidney damage and ultimately to kidney failure.
Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.

Pioneering research and expertise in action. Through innovati drive new product innovation that creates value for our.

Investment focus

Life Science, Biotechnology, Marine Technology
Seed
Ireland

Portfolio highlights

Pure Ocean Algae — Pure Ocean Algae is a biotechnology company that integrates value chains from macro-algae and other marine resources. The company has over the winter of 2019/20 deployed its first trial lines of Palmaria palmata to sea, with initial results being extremely positive. It has also taken primary research in tank-based vegetative production andsucceeded in developing a pilot commercial plant that can produce commercial volumes of Palmaria palmata, at levels approaching 100% per week.

Investors by industry

Artificial intelligence